What are the recommended dosing guidelines for Latuda (lurasidone) in adults with bipolar I depression and schizophrenia, including dose adjustments for moderate (Child‑Pugh B) and severe (Child‑Pugh C) hepatic impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Latuda Dosing Guidelines

Schizophrenia

For adults with schizophrenia, start Latuda at 40 mg once daily with food (at least 350 calories), with an effective dose range of 40-160 mg/day and maximum dose of 160 mg/day; no initial titration is required. 1

  • Adolescents (13-17 years): Start at 40 mg once daily, effective range 40-80 mg/day, maximum 80 mg/day 1
  • Administration with food is mandatory—it increases absorption approximately 2-fold (AUC) and 3-fold (Cmax) 1

Bipolar I Depression

For adults with bipolar I depression, start Latuda at 20 mg once daily (whether as monotherapy or adjunctive to lithium/valproate), with an effective range of 20-120 mg/day and maximum dose of 120 mg/day; notably, higher doses (80-120 mg/day) did not provide additional efficacy compared to lower doses (20-60 mg/day) in monotherapy studies. 1

The optimal therapeutic dose based on recent meta-analysis is 40-60 mg daily (specifically 50 mg showed SMD -0.60 for depression improvement), balancing efficacy with side effect profile 2. This dose range demonstrates:

  • Superior depression reduction (SMD -0.60)
  • Improved anxiety (SMD -0.32)
  • Better clinical global impression (SMD -0.67)
  • Reduced disability (SMD -0.38)

Pediatric patients (10-17 years): Start at 20 mg once daily, may increase after one week based on response, effective range 20-80 mg/day, maximum 80 mg/day. In clinical studies, 67% of patients received 20-40 mg/day at study end 1

Hepatic Impairment Dosing

For moderate hepatic impairment (Child-Pugh B, score 7-9), start at 20 mg/day with a maximum dose of 80 mg/day. 1

For severe hepatic impairment (Child-Pugh C, score 10-15), start at 20 mg/day with a maximum dose of 40 mg/day. 1

These dose reductions are necessary because patients with moderate to severe hepatic impairment have higher lurasidone exposure, increasing the risk of adverse reactions 1

Renal Impairment Dosing

For moderate renal impairment (CrCl 30 to <50 mL/min) or severe renal impairment (CrCl <30 mL/min), start at 20 mg/day with a maximum dose of 80 mg/day. 1

Drug Interaction Adjustments

  • Contraindicated: Do not use with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir, voriconazole) 1
  • Moderate CYP3A4 inhibitors: Dose adjustment required (specific guidance in full prescribing information) 1

Critical Administration Points

  • Always administer with food (minimum 350 calories) to ensure adequate absorption 1
  • No initial dose titration required for standard adult dosing in schizophrenia or bipolar depression 1
  • For bipolar depression specifically, the 20-60 mg/day range appears optimal based on efficacy data, as the 80-120 mg/day range showed no additional benefit 1, 2

Special Population Considerations

  • Elderly: No specific dose adjustment required based on age alone, though 20 mg/day showed similar concentrations to younger patients 1
  • Asian patients: Expert consensus supports 20 mg/day starting dose with titration up to 120 mg/day for adults, 20-80 mg/day for elderly 3
  • No adjustment needed for sex, race, or smoking status 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.